title: The effect of the renin-angiotensin-aldosterone system inhibition on myocardial function in early and late phases of dilated cardiomyopathy in Tgaq*44 mice.
abstract: BACKGROUND
  The renin-angiotensin-aldosterone system (RAAS) determines progression of heart failure (HF) in humans, and RAAS inhibition is a major therapeutic strategy in HF.
  
  
  OBJECTIVE
  To assess the effect of angiotensin-converting enzyme inhibitor (ACE-I) and aldosterone receptor antagonist (ARA) therapy on the development of HF at its early and late stage in a murine model of dilated cardiomyopathy (Tgaq*44 mice).
  
  
  METHODS
  Tgaq*44 mice at the early or advanced stage of HF received combined therapy including ACE-I (perindopril 2 mg/kg) and ARA (canrenone 20 mg/kg). Cardiac function was assessed by magnetic resonance imaging before and after 2 months of treatment.
  
  
  RESULTS
  Combined therapy with perindopril and canrenone resulted in preserved systolic function at the early stage and reduced chamber dilatation at the advanced stage of HF in Tgaq*44 mice.
  
  
  CONCLUSIONS
  Activation of the RAAS is involved in progression of HF in Tgaq*44 mice with dilated cardiomyopathy. Therapeutic efficacy of ACE-I and ARA to inhibit systolic dysfunction and cardiac chamber dilation depends on the stage of HF development.
authors.affiliation: Department of Experimental Pharmacology, Chair of Pharmacology, Jagiellonian University Medical College, Krakow, Poland.
authors.forename: Mirosław
authors.initials: M
authors.lastname: Woźniak
authors.forename: Urszula
authors.initials: U
authors.lastname: Tyrankiewicz
authors.forename: Lukasz
authors.initials: L
authors.lastname: Drelicharz
authors.forename: Tomasz
authors.initials: T
authors.lastname: Skórka
authors.forename: Magdalena
authors.initials: M
authors.lastname: Jabłońska
authors.forename: Sylwia
authors.initials: S
authors.lastname: Heinze-Paluchowska
authors.forename: Stefan
authors.initials: S
authors.lastname: Chłopicki
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D002192:Canrenone / Q000494:pharmacology; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004280:Dobutamine / Q000494:pharmacology; D006333:Heart Failure / Q000188:drug therapy* / Q000517:prevention & control; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D020913:Perindopril / Q000494:pharmacology; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D004280:Dobutamine; D002192:Canrenone; D020913:Perindopril